Building on Bruker’s proprietary Opto-Electrical Positioning (OEP) technology and scalable OptoSelect™ microfluidic chips, Beacon Discovery complements the floor-standing premium Beacon® platforms.

Preliminary SpotLight™ Human Lambda reagent data to be showcased by GSK at the 16 th annual PEACe Conference EMERYVILLE, Calif., Sept. 21, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), a ...

Bruker Corporation today announced the launch of the Beacon Discovery ™ Optofluidic System at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025. This new Beacon benchtop ...

Successfully producing large quantities of biotherapeutics, including monoclonal antibodies and recombinant protein products, depends on robust and reliable cell line development (CLD). Issues that ...

Advances in cell line engineering and microfluidic technologies offer substantial opportunities to shorten timelines in cell line development (CLD). However, as with any innovation, optimizing these ...